Depakine is an antiepileptic drug that has a central muscle relaxant and sedative effect.
Release form and composition
The following Depakin dosage forms are produced:
- Syrup in bottles of 100 ml. The active ingredient is sodium valproate (5.764 g per 100 ml). Auxiliary substances of the syrup are: sorbitol, sucrose, cherry flavoring, glycerol;
- Depakine enteric 300 tablets containing 300 mg of sodium valproate in 1 piece, as well as auxiliary components: sodium saccharinate, ethylcellulose, hypromellose, titanium dioxide, macrogol, talc, polyacrylate dispersion 30%;
- Depakine Chrono 500 tablets of prolonged action with 500 mg of sodium valproate in 1 piece, as well as excipients: sodium saccharinate, ethylcellulose, hypromellose, titanium dioxide, macrogol, talc, polyacrylate dispersion 30%;
- Lyophilisate for preparation of a solution for intravenous administration in glass vials of 400 mg each, containing 400 mg of sodium valproate. As a solvent, use volda for injection 4 ml.
Indications for use
According to the instructions, Depakin is indicated for use in:
- Epilepsy of various genesis;
- Epileptic seizures, including generalized and partial seizures, as well as seizures occurring against the background of various organic brain diseases;
- Character and behavior changes;
- Manic-depressive psychosis, characterized by bipolar character, which is not amenable to therapy with lithium drugs, specific syndromes (West or Lennox-Gastaut);
- Children's ticke;
- Febrile convulsions in children.
According to the instructions, Depakin is contraindicated for use in the following cases:
- Hypersensitivity to the active or auxiliary components of the drug;
- Liver failure;
- Hemorrhagic diathesis;
- First trimester of pregnancy and breastfeeding;
- Acute and chronic hepatitis;
- Pancreas dysfunction;
- Children under three years old (with the exception of syrup).
Depakine is prescribed with caution when:
- Mental retardation (especially children);
- Organic bone marrow diseases;
- Oppression of bone marrow hematopoiesis;
- Renal failure;
- Congenital fermentopathies;
- Pancreatic and liver diseases.
Dosing and Administration
Depakin tablets are taken orally, without chewing and squeezing half a glass of water, before or immediately after a meal, two or three times a day. The dosage is determined individually by the attending physician, depending on the severity of the symptoms and the effectiveness of the therapy.
Depakin syrup before use can be mixed with liquid or added to a small amount of food. As a monotherapy in children and adults, the initial dose of syrup is 5-15 mg per kg of body weight per day. If necessary, it is allowed its gradual increase once a week by 5-10 mg per kg of weight. The maximum daily dose of syrup is 30 mg per kg of body weight.
When conducting a combined treatment for adults, Depakin Syrup is prescribed at a dose of 10-30 mg per kg of body weight per week, increasing it by 5-10 mg per kg of body weight per week. Children should be prescribed 15-45 mg per kg of body weight per week, the maximum figure should not exceed 50 mg per kg of body weight per week. The duration of Depakin use is determined by the attending physician individually, and he also adjusts the dose.
Depakine lyophilisate is used as a replacement therapy and in situations requiring the rapid achievement and maintenance of the required level of valproic acid in the blood plasma. The average dose is 15-30 mg per kg of body weight per day.
Depakin use can cause the following adverse reactions from various systems of vital activity of the organism:
- Central nervous system: changes in behavior, mental state, mood, trembling of hands or hands, diplopia, irritability, motor restlessness, headache, agitation, incoordination, drowsiness, dizziness, spots before eyes;
- Blood coagulation system: prolongation of bleeding time, thrombocytopenia;
- Digestive system: abdominal and stomach cramps, diarrhea, loss of appetite, nausea, pancreatitis, constipation, vomiting, digestive disorders;
- Metabolism: a sharp increase or decrease in body weight;
- Skin reactions: alopecia;
- Allergies: skin rash;
- Other: irregular menstruation.
Valproic acid should be prescribed to patients who take anticonvulsants with minimum doses, gradually being brought to the required amount over 2 weeks. Cancellation of anticonvulsants should also be carried out gradually. In patients who do not take anticonvulsants, the effective dose of Depakine can be achieved after 1 week.
When conducting a combination of anticonvulsant therapy increases the likelihood of side effects from the liver. At the time of drug therapy, patients are advised to monitor the picture of peripheral blood, liver function, condition of the blood coagulation system (especially in the first six months of treatment).
In children, there is a risk of a severe and even life-threatening hepatotoxic effect.
At the time of treatment with Depakine, it is necessary to carefully manage potentially dangerous mechanisms that require increased concentration of attention.
Depakin is contraindicated in the first trimester of pregnancy. If there is a need to use Depakine in the second and third trimesters, it is necessary to take into account that valproic acid can cause various anomalies in the fetus.
Structural analogues of Depakine are:
- Valproic acid;
- Sodium Valproate;
Terms and conditions of storage
According to the instructions, Depakin stored in a dry, cool, dark place out of the reach of children. The shelf life of Depakine syrup is 3 years, the remaining dosage forms are 5 years.